2002 Subject Index

Volume 23, Numbers 1-26

Entries are organized alphabetically by subject matter and key words, with entries followed by the issue number and page number (e.g., issue number 2, page 20 would be listed as 2:20). Tables are indicated by a lowercase t, figures by a lowercase f. Supplements are indicated by an uppercase S.

A

Abacavir, 538Z:6t

ABC mnemonic for organic mimics, 20:236-238, 237t

Abdominal pain

  • high-risk patients, 536Z:6
  • right lower quadrant, in women, 1:1-13, 2t, 3f
  • Abrasions, 26:316
  • corneal, 13:167

Abscesses

  • in deep spaces in hand, 25:307, 308f
  • felon, 25:304-305
  • perforated appendicitis and, 1:7-8, 8f

Abuse

  • child, 6:69, 71f

sexual

  • behavioral indicators of, 6:70, 72t
  • complaint/exam indicators of, 6:70, 72t
  • differential diagnosis of, 6:75-76
  • examination, 6:71
  • pediatric, 6:69-76
  • physical examination techniques for, 6:72
  • specialized forensic exam techniques for, 6:72-73

ACC. See American College of Cardiology

ACEIs. See Angiotensin-converting enzyme inhibitors

Acetabulum, Trauma 4:3, 4f

  • fractures of, Trauma 4:9-10
  • radiographic lines of, Trauma 4:4-5, 5f

Acetaminophen

  • for pain management, 5:55, 56t
  • warfarin interactions, 12:154, 155t

Acidic substances, 13:170t

ACS. See Coronary syndrome, acute

Actinomyces israelii, 1:9

Acute hand, 23:275-283, 24:287-299, 25:303-311

  • examination of, 23:279-282
  • initial evaluation of, 23:279-280
  • motor function evaluation of, 23:282
  • neurological evaluation of, 23:281-282
  • sensation evaluation of, 23:281-282
  • vascular status of, 23:280-281
  • what not to do with, 23:281t, 283

Acute hydrocele/varicocele, 2:25

Acute pain, 5:64

Acute retroviral syndrome (ARS), 538Z:3

  • diagnosis of, 538Z:3-4
  • differential diagnosis of, 538Z:3, 3t

Acute scrotum, 2:19-20, 19t

Acute wounds, 26:324t

Acyclovir, 6:77t

Adenosine, 4:49, 4S

Adnexal torsion, 1:5-6, 7t

Adolescents, 537Z:6-7

Adrenaline, 22:267-269, 268t

Adrenal insufficiency, 20:241

Advance directives, 537Z:5

Adverse drug effects

  • with anthrax drugs, 6S:3
  • diagnosis of, 12:155-156
  • in elderly, 11:147, 147t
  • legal considerations for, 12:156
  • reporting, 12:159
  • with sedation and analgesia, 22:269t
  • strategies to prevent, 12:157t, 158t

AF. See Atrial fibrillation

Agitation, 21:255t

AHA. See American Heart Association

Airborne anthrax, 11S:4

Airway problems, 20:236-237, 238t

  • indicators of, 22:264, 266t
  • pre-procedural examination of, 22:264, 266t

Alcoholism, 9:112t

Alcohol withdrawal syndrome, early-onset, 20:238

Alfentanyl, 21:257

Alkali substances, 13:170t

Allen test, 23:280-281, 281f

Alprazolam, 22:267

Alternative drug therapy, 12:158

American College of Cardiology/American Heart Association (ACC/AHA) heart failure classification, 7:89t

American Society of Anesthesiologists (ASA)

  • classifications, 22:264-265, 265t
  • physical status classification of, 21:249, 250t

Amethocaine. See Tetracaine

Aminoglycoside, 9:112t, 119, 10:132, 137t, 138

Amiodarone

  • for brady-tachy syndrome, 19:227, 228t
  • for cardioversion, 19:225
  • for cardioversion of AF, 19:222, 223t
  • for CHF/LV dysfunction, 19:227, 228t
  • digoxin interactions, 12:155
  • for ischemic heart disease/MI, 19:227, 228t
  • for rate control, 19:220
  • for sinus rhythm maintenance, 19:226
  • for SVT, 4S
  • warfarin interactions, 12:155t

Amitriptyline, 5:63

Amoxicillin

  • for CAP, 9:114t, 10:140t
  • for UTI, 1:11

Amoxicillin/clavulanate

  • for bites, 26:324
  • for CAP, 9:114t, 10:140t

Amphetamines, 12:155

Ampicillin

  • for acute bacterial prostatitis, 3:35
  • for acute cholangitis, 17:207, 208t, 209

Ampicillin/sulbactam, 9:112t, 113t, 114t, 119, 10:137t, 139t, 140t

Amputations

  • fingertip, 24:297, 297f, 298f
  • hand
  • replantation of, 24:296, 298t
  • traumatic, 24:296-297
  • treatment advances, 24:297-298

Analgesia

  • adult, agents for, 21:253t-255t
  • adverse events, 22:269t
  • definition of, 21:248
  • implanted devices for, 5:64
  • levels of, 21:248, 249t
  • pediatric, drugs and reversal agents for, 21:255t-266t
  • post-sedation and analgesia discharge criteria, 22:269, 269t
  • for right lower quadrant abdominal pain in women, 1:3

Anatomy

  • of eye, 13:163, 165f
  • of hand, 23:276-279
  • of pediatric sexual abuse, 6:73-74
  • of pelvis, Trauma 4:2-3
  • of penis, 3:31f
  • of prostate, 3:34
  • of sacroiliac complex, Trauma 4:2-3
  • of scrotum, 2:19, 19f
  • of testis, 2:19, 19f

Anesthesia

  • local, 26:318, 318t
  • topical, 22:268t
  • wound, 26:318-319

Angiodysplasia, Geriatric 1:5-6

Angiography

  • lower GI, Geriatric 1:10
  • pulmonary, 14:170

Angiotensin-converting enzyme inhibitors (ACEIs)

  • contraindications to, 8:96, 96t
  • drug interactions, 12:154
  • for heart failure, 8:96-97, 96t
  • NSAID interactions, 12:155

Angiotensin receptor blockers (ARBs), 8:96t, 97

Animal bites, 25:309-310, 26:324-325

  • rabies prophylaxis recommendations for, 26:325, 325t
  • wounds with increased risk for infection, 26:325t

Anisocoria, 13:174

Anoscopy, Geriatric 1:10

Anthrax

  • aftermath, 6S:1-4
  • airborne, 11S:4
  • extended treatment of, 6S:1-4
  • fear of, 12S:1-3

Anthrax drug adherence, 6S:3

Anthrax mailer, 9S:3-4

Antiarrhythmics

  • class IA
  • for cardioversion, 19:222-223, 223t, 225
  • for rate control, 19:222t
  • class IC, 19:223, 223t, 225
  • class III, 19:223t, 224-225
  • contraindications to, 8:105
  • digoxin interactions, 12:155

Antibiotics

  • for acute cholangitis, 17:207, 208t
  • for anthrax, adherence to, 6S:3
  • for appendicitis, 1:8-9
  • for CAP, 9:119-120, 10:131, 136-138, 138-139
  • daily drug costs, 9:116, 117t
  • for hospital-based management of CAP, 9:116-117, 10:129-142
  • ophthalmic, 13:168t
  • for pelvic inflammatory disease, 1:9
  • prophylactic, 26:323-324, 324t
  • for pyelonephritis, 1:11
  • topical, 26:322
  • warfarin interactions, 12:154, 155t

Anticoagulation therapy, 8:104, 15:176-177

  • complications of, 15:183-185
  • duration of, 15:183, 184t
  • guidelines for AF, 19:226, 226t
  • importance of, 19:226
  • inpatient, 8:104
  • outpatient, 8:104
  • patient acceptance of, 15:184
  • patient education about, 15:180-181
  • special considerations for, 15:183-185
  • for VTE, 15:181-183

Anticonvulsants, 5:63

Antidepressants, 5:62-63

Antiemetics, 17:208

  • for adnexal torsion, 1:6
  • for medication-induced nausea and vomiting, 5:59

Antifungals, 12:155t

Antihistamines

  • drug interactions, 11:150
  • for medication-induced nausea and vomiting, 5:59

Antimicrobial Resistance Management (ARM) Database, 9:122-123

Antimicrobial therapy

  • appropriate and adequate intensity of, 9:120
  • for CAP, 9:109-122, 112t, 113t, 10:129-142, 139t

Antipsychotics, 11:150

Antispasmodic agents, 17:208

Anxiolytic drugs, 21:248

Appendicitis, 1:6-9

  • perforated, 1:7-8, 8f
  • uncomplicated, 1:7-8, 8f

Appendix testis/epididymis, torsion of, 2:24-25

ARBs. See Angiotensin receptor blockers

Arrhythmias

  • atrial tachyarrhythmias, 4:42t
  • atrioventricular tachyarrhythmias, 4:42t
  • ventricular, 8:105

Arterial blood gases, 14:168

Arteries, hand, 23:277-278

Arthritis, septic, 25:305-306

ASA. See American Society of Anesthesiologists

ASCAP (Antibiotic Selection for Community-Acquired Pneumonia) Panel

  • guidelines for empiric antimicrobial therapy, 9:112t, 10:137t
  • recommendations for outpatient management, 10:130-131
  • treatment guidelines, 10:131-133
  • Year 2002 Consensus Report Panel and Scientific Roundtable, 9:111

Aspirin

  • for AF, 19:226, 226t
  • for pain management, 5:55, 56t
  • warfarin interactions, 12:154

Assent and dissent, 537Z:4

Association for Professionals in Infection Control and Epidemiology (APIC), 12S:3-4

Atenolol, 19:226

Ativan. See Lorazepam

Atrial fibrillation, 4:44f, 45, 47t, 18:211-216

  • anticoagulation guidelines for, 19:226, 226t
  • chronic, 18:214t
  • classification of, 18:212, 214t
  • clinical presentation of, 18:215
  • coexisting illnesses, 19:226-228, 228t
  • conditions associated with, 18:212-213
  • diagnostic studies for, 18:215
  • ECG findings in, 18:215-216, 216t, 217f
  • electrophysiologic mechanisms of, 18:213
  • epidemiology of, 18:212-213
  • etiology of, 18:213-215
  • exercise-induced, 19:227-228, 228t
  • hemodynamic effects of, 18:214
  • hemostatic markers of, 18:214
  • management of, 19:219-229
  • medications for pharmacological cardioversion of, 19:222-223, 223t
  • medications for rate control in, 19:220, 222t
  • neurogenic, 19:227, 228t
  • outcome of, 18:213
  • paroxysmal, 18:214t
  • pathophysiology of, 18:213-215
  • patient disposition in, 19:229
  • post-surgical, 19:227, 228t
  • prevalence of, 18:212, 215t
  • recent-onset, 18:214t
  • risk factors for, 18:215t
  • risk factors for stroke in, 19:224t
  • signs and symptoms of, 18:215
  • special conditions in, 19:226-228, 228t
  • stroke outcome for, 18:213
  • treatment of, 4:46, 49f
  • algorithm for, 19:221f
  • goals for, 18:213t
  • nonpharmacological, 19:228

Atrial flutter, 4:44, 47t

  • with 2:1 block, 4:44, 44f
  • with 4:1 conduction, 4:44, 44f

Atrial remodeling, 18:213-214

Atrial tachyarrhythmias, 4:42t

Atrial tachycardia, 4:43f, 44, 47t

  • ectopic, 4:44
  • multifocal, 4:43, 43f, 47t

Atrioventricular nodal reentrant tachycardia (AVNRT), 4:45-46, 45f, 46f, 47t

Atrioventricular node, 18:214

Atrioventricular reentrant tachycardia (AVRT), 4:46, 47t, 48f

Atrioventricular tachyarrhythmias, 4:42t

Avulsion injuries, pelvic, Trauma 4:8-9

Avulsions, 26:316

Azithromycin, 9:122-123

  • for acute epididymitis, 2:24
  • for CAP, 9:112t, 113t, 114t, 123, 10:132, 133, 136, 137t, 139, 139t, 140t
  • for cervicitis, 1:10t
  • for chlamydia, 1:10t, 6:77t
  • daily cost, 9:117t
  • for N. gonorrhoeae treatment, 6:77t
  • for urethritis, 3:37

AZT. See Zidovudine

Aztreonam

  • for acute cholangitis, 17:208t
  • for CAP, 9:119
  •  
B

Bacitracin ophthalmic ointment, 13:168t

Baclofen, 5:62t

Bacterial endocarditis, 20:241-242

Bacterial keratitis, 13:171-172

Bacterial prostatitis, acute, 3:34-35

Bacterial vaginosis, 6:77t

Bacteroides

  • antimicrobial therapy for, 9:119
  • in cholecystitis/cholangitis, 17:205t
  • in pelvic inflammatory disease, 1:9

Bacteroides fragilis

  • antimicrobial therapy for, 9:119-120
  • in Fournier’s gangrene, 3:34

Bactrim. See Trimethoprim/sulfamethoxazole

Balanitis, 3:31

Barbiturates, 21:251-252

Barium enema, Geriatric 1:10

Barrier precautions, Trauma 3:5

BCA. See Bichloroacetic acid

Behavioral indicators of sexual abuse, 6:72t, 79

Bell-clapper deformity, 2:20-21, 21f

Bennet’s fractures, 24:289t

Benzodiazepines

  • antagonists, 21:257-258
  • for procedural sedation, 21:252

Beta-blockers, 19:220

  • for brady-tachy syndrome, 19:227, 228t
  • CCB interactions, 12:154-155, 156t
  • for CHF/LV dysfunction, 19:227, 228t
  • contraindications to, 8:97t
  • for exercise-induced AF, 19:227-228, 228t
  • for heart failure, 8:97-98, 97t
  • for neurogenic AF, 19:227, 228t
  • NSAID interactions, 12:155
  • for rate control in AF, 19:222t
  • for thyrotoxicosis, 19:227, 228t

Beta-lactam/beta-lactamase inhibitor, 9:112t, 113t, 114t, 119, 121-122, 10:131-132, 132, 137t, 138, 139, 139t, 140t

Bichloroacetic acid (BCA), 6:77t

Biliary tract disorders, 17:203-209

Bioimpedance monitoring, 7:90-91

Bioterrorism, 2S:1-4, 6S:1-4, 9S:1-4, 11S:1-4, 12S:1-4

  • anthrax mailer, 9S:3-4
  • forensics, 9S:4
  • planning for, 12S:4
  • tabletop exercises, 11S:2, 3

Bites, 25:309-310

  • animal, 25:309-310, 26:324-325, 325t
  • fight, 25:305t, 309, 26:324
  • human, 26:324, 325t

Bleeding. See also Hemorrhage

  • gastrointestinal, Geriatric 1:7t
  • with heparin, 15:182
  • lower GI, Geriatric 1:1-11
  • upper GI
  • acute, Geriatric 1:5f
  • sites, Geriatric 1:8

Blepharitis, 13:170

Blister agents, 2S:3

Blood, Trauma 3:7

Blood substitutes, Trauma 3:8

Body composition, 11:148

Botanicals, 12:155t

Brady-tachy syndrome, 19:227, 228t

Breach of duty, 536Z:3

Breast development, 6:73t

Breathing problems, 20:236-237, 238t

Brevital. See Methohexital

British Anti-Lewisite (BAL), 2S:3

Bromelains, 12:155t

Brown bag syndrome, 11:146

B-type natriuretic peptide, 7:89-90

Bumetanide

  • for acute heart failure, 8:98t
  • for acute pulmonary edema, 8:95

Bupivacaine (Marcaine), 26:318t

Bupivacaine with epinephrine, 26:318t

Buprenorphine

  • for pain management, 5:62
  • starting dose, 5:61t

Burns/chemical exposure, ocular, 13:168-169

Butorphanol, 5:61t

C

Calcium, 18:214

Calcium channel blockers (CCBs)

  • for CHF/LV dysfunction, 19:227, 228t
  • contraindications to, 8:104
  • drug interactions, 12:154-155, 156t
  • for rate control in AF, 19:222t

Calf vein thrombosis, 15:186

California, 535Z:5t

Cancer

  • colorectal, Geriatric 1:6
  • penile, 3:34
  • prostate, 3:35
  • testicular, 2:26

Candida albicans, 6:76

CAP. See Community-acquired pneumonia

Capnocytophaga canimorsus, 26:324

Capsaicin, 5:62

Captopril, 8:96t

Carbamazepine

CCB interactions, 12:156t

  • for pain management, 5:63

Cardiac ICU, 8:105t

Cardiac monitoring, 7:88

Cardiac output, low, 7:87, 87t

Cardiogenic shock, 7:85, 8:105

  • diagnosis of, 7:85, 85t
  • etiologies of, 7:84, 84t
  • management strategies for, 8:95

Cardiologists, 19:229

Cardiovascular disturbances, 20:237-238, 238t

Cardiovascular function, 11:148-149

Cardioversion, 19:220-225

  • complications of, 19:225
  • electrical
  • considerations for, 19:223-224
  • pharmacologically augmented, 19:224
  • hemodynamic changes after, 18:215
  • medications for, 19:224-225
  • methods for, 19:225
  • pharmacological, 19:222-223, 224

Carisoprol, 5:62t

Carvedilol

  • for chronic systolic heart failure, 8:97t
  • for heart failure, 8:97

Cat bites, 26:325, 325t

Catheter ablation, endocardial, 19:228

Catheters. See also Foley catheter

  • epidural, 5:64

Causation, 536Z:3

Caval filters, 15:185-186

Cavernous sinus thrombosis, 13:174-175

CCBs. See Calcium channel blockers

Cefadroxil, 1:11

Cefepime, 9:112t

  • for CAP, 9:113t, 10:137t, 139t

Cefixime, 1:10t, 6:77t

Cefmetazole, 9:119

Cefoperazone, 9:119

Cefotaxime

  • for CAP, 9:112t, 113t, 114t, 119, 10:133, 137t, 138, 139t, 140t
  • daily cost, 9:117t
  • for S. pneumoniae, 9:122-123
  • year 2002 NCCLS breakpoints, 9:119

Cefotetan, 9:119

Cefoxitin, 9:119

Ceftazidime, 9:119

Ceftizoxime, 10:138

Ceftriaxone

  • for acute epididymitis, 2:24
  • breakpoints, 9:119
  • for CAP, 9:112t, 113t, 114t, 119, 121-122, 10:131-132, 137t, 138, 139, 139t, 140t
  • for conjunctivitis, 13:171
  • daily cost, 9:117t
  • for gonorrhea, 1:10t, 6:77t
  • for pyelonephritis, 1:11
  • for S. pneumoniae, 9:122-123
  • for urethritis, 3:37

Cefuroxime, 9:114t, 119, 10:138, 140t

Celecoxib, 5:57t, 58

Cell-saver techniques, Trauma 3:8

Cellulitis

  • hand, 25:306
  • periorbital (preseptal)/orbital, 13:173

Centers for Disease Control and Prevention (CDC)

Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group (CDC-DRSPWG)

  • guidelines for antibiotic therapy of CAP, 10:138-139
  • recommended year 2000 empiric regimens for CAP, 9:114t, 10:140t
  • extended anthrax treatment offer, 6S:1-4
  • recommendations for action against bioterrorism, 9S:2
  • recommendations for tetanus prophylaxis, 26:323
  • smallpox plan, 12S:3-4

Central nervous system disturbances, 20:237-238, 238t

Central retinal artery occlusion, 13:173-174

Central retinal vein occlusion, 13:174

Cephalosporins

  • for bites, 26:324
  • for CAP, 9:113t, 119, 10:131-132, 138
  • for fingertip amputation, 24:297
  • third-generation
  • for acute cholangitis, 17:208t, 209
  • for CAP, 9:119

Cervicitis, 1:9, 10t

Chalazia, 13:171

Chemical exposures

  • ocular, 13:168-169, 170t
  • signs and symptoms of, 2S:3
  • triage, 2S:2

Chest pain, 536Z:5-6

Chest radiography (CXR)

  • in heart failure, 7:90, 91t
  • portable, 7:91t
  • in venous thromboembolism, 14:167-168

Child abuse, 6:69, 71f

Children. See also Pediatric patients

  • assent or dissent from, 537Z:4
  • NPO status for, 22:263-264, 264t
  • pain control in, 5:65
  • STD testing and prophylaxis for, 6:75

Children’s rights, 537Z:1-9

Chlamydia

  • in acute epididymitis, 2:24
  • empiric antibiotic coverage for, 10:136
  • in PID, 1:9
  • prophylaxis of, 6:77t
  • treatment of, 1:10t, 6:77t

Chlamydia pneumoniae

  • antimicrobial therapy for, 9:119, 120
  • combination therapy for, 9:123, 10:132
  • outpatient management of, 10:130, 131
  • in pneumonia, 10:136, 138, 139t

Chlamydia psittaci, 10:138

Chlamydia trachomatis, 3:37

Chloral hydrate

  • for procedural sedation, 21:250
  • for sedation for pediatric CT and MRI scans, 22:267

Chloride, 2S:3

Chlorphenesin, 5:62t

Chlorpromazine (Phenergan), 21:249

Chlorzoxazine, 5:62t

Cholangitis

  • acute, 17:208t
  • antibiotics for, 17:207
  • bacterial pathogens associated with, 17:205
  • clinical manifestations of, 17:205, 206t

Cholecystitis, 17:203-209

  • bacterial pathogens associated with, 17:205, 205t
  • clinical presentation of, 17:205, 206t
  • complications of, 17:207-208
  • diagnosis of, 17:205-206
  • differential diagnosis of, 17:206-207
  • pathophysiology of, 17:204-205
  • treatment of, 17:208-209

Cholelithiasis, 17:203-209

  • bacterial pathogens associated with, 17:205t
  • clinical presentation of, 17:205, 206t
  • complications of, 17:207-208
  • diagnosis of, 17:205-206
  • differential diagnosis of, 17:206-207
  • pathophysiology of, 17:204-205
  • treatment of, 17:208-209

Choline magnesium trisalicylate, 5:56t

Chronic pain, 5:64-65

Ciprofloxacin (Cipro)

  • for acute cholangitis, 17:207, 208t
  • for acute epididymitis, 2:24
  • for CAP, 9:112t, 113t, 10:137t, 139t
  • daily cost, 9:117t
  • drops, 13:168t
  • for gonorrhea, 1:10t, 6:77t
  • for pyelonephritis, 1:11
  • resistance to, 10:135
  • for UTI, 1:10
  • warfarin interactions, 12:154, 155t

Clarithromycin, 9:122-123

  • for CAP, 9:113t, 114t, 10:139, 139t, 140t
  • digoxin interactions, 12:155
  • warfarin interactions, 12:154, 155t

Clavulanate

  • for acute cholangitis, 17:208t
  • for bites, 26:324
  • for CAP, 9:112t, 114t, 10:133, 137t, 140t

Cleaning the hand, 23:282

Clenched-fist injuries, 26:324

Clindamycin

  • for acute cholangitis, 17:208t, 209
  • for CAP, 9:112t, 113t, 119, 10:132, 137t, 139t
  • for gonorrhea, 1:10t

Clinical guidelines/pathways, 12:157-158

Clitoris, 6:73

Clonidine, 5:62

Closed head injury, Trauma 3:9

Clostridium

  • in cholecystitis/cholangitis, 17:205, 205t
  • in infectious diarrhea, Geriatric 1:9

CLOT (Cost-Lowering Options for optimizing outcomes in Thrombosis) analysis, 16:199

Coagulation factors, Trauma 3:7

Cocaine

  • serotonergic drug interactions, 12:155
  • TAC solution or gel, 22:267-269, 268t

Codeine

  • for pain management, 5:60-61
  • starting dose, 5:61t

Colitis

  • diversion, Geriatric 1:9
  • ischemic, Geriatric 1:6-7
  • ulcerative, Geriatric 1:9

Collateral ligaments, 23:276, 277f, 24:290f

Colloids, Trauma 3:6

Colonic diverticulosis, Geriatric 1:4-5

Colonic polyps, Geriatric 1:9

Colonic varices, Geriatric 1:9

Colonoscopy, Geriatric 1:10

Colorectal carcinoma, Geriatric 1:6

Communication with staff, 12:158

Community-acquired pneumonia (CAP)

  • antibiotic therapy for
  • consensus guidelines for, 10:138-139
  • empiric, 10:136-138
  • selection for hospitalized patients, 9:116-117, 10:129-142
  • antimicrobial therapy for, 9:119-120, 10:129-142
  • empiric, 9:112t, 113t, 10:137t
  • guidelines for, 9:112t, 113t, 10:139t
  • ASCAP 2002 Consensus Report Panel and Scientific Roundtable, 9:111
  • ASCAP treatment guidelines for, 10:131-133
  • combination therapy for, 9:123, 10:131-133
  • critical pathways and protocols for, 10:132
  • diagnosis of, 9:111-115
  • empiric therapy for, 9:114t, 10:140t
  • epidemiology of, 9:111-115
  • evaluation of, 9:111-115
  • in-hospital management of, 9:115-116, 10:131-133
  • guidelines for, 9:109-122, 10:137t, 139t
  • initial stabilization and adjunctive measures for, 9:113-115
  • outcome-effective strategies for, 9:109-122
  • outcome-optimizing regimens for, 9:121-122
  • outpatient management of, 9:115-116
  • ASCAP consensus panel recommendations for, 10:130-131
  • guidelines for, 10:137t, 139t
  • pathogens in, 10:138
  • patient disposition in, 9:115
  • patient management recommendations, 10:130-131
  • prevention of DVT in, 10:139-142
  • prognostic scoring for, 9:115-116
  • signs and symptoms of, 9:113
  • treatment guidelines for, 9:120-121

Compartment syndrome, 25:310

Computed tomography. See CT scans

Confidentiality, 537Z:7-8

Congestive heart failure, 19:227, 228t

DVT prevention in, 7S, 8S, S02101:3t

Conjunctivitis, 13:171

Conscious sedation

  • definition of, 21:248
  • sample discharge instructions form, 22:270f

Consent

  • for emergency treatment, 537Z:4
  • informed, 537Z:1-3, 3-4
  • by minors, 537Z:4-5

Constipation, Geriatric 1:9

Consultation

  • with cardiologist, 19:229
  • drug information resources, 12:157t
  • with ophthalmologist, 13:175

Corneal abrasion, 13:167

Corneal foreign bodies, 13:167

Corneal lacerations, 13:169

Coronary syndrome, acute (ACS), 8:101-102

Coumadin, 12:155

Counseling, stress, 11S:1-4

COX-2 inhibitors, 5:58

Coxiella burnetti, 10:138

Crohn’s disease, Geriatric 1:9

Crush wounds, 26:316

Cryotherapy, 6:77t

Crystalloids, Trauma 3:6

CT scans, Geriatric 1:10

  • helical, 14:169
  • pediatric, 22:266-267
  • sedation for, 22:266-267
  • for venous thromboembolism, 14:169

Cushing’s syndrome, 20:241

Cyanide, 2S:3

Cyanocrylate glues, 13:169

Cyclobenzaprine, 5:62t

Cytochrome P450 enzyme inhibitors and inducers, 11:149t, 150

Cytomegalovirus (CMV) retinitis, 13:175

D

Dacrocystitis, 13:170

Damage caps, 536Z:4

Damages, 536Z:3

Danshen, 12:155t

D-dimer test

  • for pulmonary embolism, 14:170f, 171
  • for venous thromboembolism, 14:169, 170f, 171

Decontamination, chemical, 2S:2

Deep space infections, 25:307-308, 308f

Deep venous thrombosis (DVT)

  • diagnostic algorithm for, 14S
  • differential diagnosis of, 14:166t, 167, 16:193, 194t
  • patient risk stratification for, 16:194-195, S02101:3-4
  • pre-test probability for, 14:167, 167t
  • prophylaxis of in community-acquired pneumonia, 10:139-142
  • exclusionary criteria for, S02101:6t, 7
  • guidelines for, 7S, 8S
  • in heart failure, S02101:1-7
  • heparins for, 15:177-178
  • indications for, S02101:2, 3t
  • MEDENOX trial, 10:141-142, 16:195-197, S02101:4-5
  • national guidelines for, 16:191-200
  • pharmacoeconomic issues and analysis, S02101:6-7
  • PRIME study group, 16:197-199, S02101:5-6
  • PRINCE study, 16:197, S02101:5
  • risk factors for hospitalized patients, S02101:1, 3t
  • SOS (Sick, Old, Surgery) DVT QuickSCREEN®, 16:193
  • treatment of, 15:175-186
  • heparins for, 15:177-178
  • hospital vs. outpatient therapy, 15:179-181

Demerol. See Meperidine

Depression, 20:243

Dermabond, 26:321

Development, 6:73t

Dexamethasone, Geriatric 2:9t

Dextromethorphan, 12:155

Diabetic retinopathy, 13:175

Diarrhea, infectious, Geriatric 1:9

Diazepam, 5:62t

  • for procedural sedation, 21:252
  • for sedation for pediatric CT and MRI scans, 22:267

Didanosine, 538Z:6t

Digoxin, 19:223

  • for brady-tachy syndrome, 19:227, 228t
  • CCB interactions, 12:154-155, 156t
  • for CHF/LV dysfunction, 19:227, 228t
  • drug interactions, 12:155
  • for heart failure, 8:98-99
  • NSAID interactions, 12:155
  • for rate control in AF, 19:220, 222t
  • for SVT, 4:49, 4S

Diltiazem

  • CCB interactions, 12:155
  • for rate control in AF, 19:220, 222t
  • for SVT, 4:49, 4S

Diphenhydramine, 26:318

  • drug interactions, 11:150
  • for medication-induced nausea and vomiting, 5:59

DIP joint dislocations, 24:291

Diprivan. See Propofol

Discharge instructions/prescriptions, 12:158-159

  • minimal criteria for early discharge, 15:182
  • post-sedation and analgesia discharge criteria, 22:269, 269t
  • for procedural sedation, 22:269-270
  • sample discharge instructions form for conscious sedation, 22:270f

Dislocations

  • DIP joint, 24:291
  • of hand bones, 24:290-291
  • lens, 13:170
  • MP joint, 24:292
  • PIP joint, 24:291, 291f

Disopyramide

  • for cardioversion, 19:222, 223t, 225
  • for neurogenic AF, 19:227, 228t
  • for sinus rhythm maintenance, 19:226

Dissent, 537Z:4

Dissociative agents, 21:254t

Dissociative sedation, 21:248

Distal phalanx fractures, 24:287-288

Distal tuft fracture, 24:289t

Disulfiram, 12:155t

Diuretics, 8:97, 98t, 99

Diversion colitis, Geriatric 1:9

Dobutamine, 8:102t, 103-104

Dofetilide

  • for cardioversion, 19:223t, 224-225
  • for CHF/LV dysfunction, 19:227, 228t
  • for ischemic heart disease/MI, 19:227, 228t
  • for rate control, 19:220
  • for sinus rhythm maintenance, 19:226

Dog bites, 26:325, 325t

Domestic violence, 535Z:1-5

Dong quai, 12:155t

Dopamine, 8:102-103, 102t

Doppler probe, 2:22, 22f

Dorsal slit procedure, 3:32, 32f

Doxycycline

  • for acute epididymitis, 2:24
  • for CAP, 9:113t, 114t, 10:139t, 140t
  • for chlamydia, 1:10t, 6:77t
  • for conjunctivitis, 13:171
  • for gonorrhea, 1:10t, 6:77t
  • for urethritis, 3:37

Dressings, 26:322-323

Droperidol (Inapsine), 21:255t, 258

Drug information resources, 12:157t

Drug interactions, 11:150, 12:155

Drug prescriptions, 12:158-159

Drugs. See also Over-the-counter (OTC) medications; specific drugs

  • of abuse (DOA), 20:238-239
  • anthrax, 6S:3
  • anxiolytic, 21:248
  • for cardioversion, 19:222-223, 223t, 224-225
  • high-risk, 12:153-155, 155t
  • hypnotic, 21:248
  • initial dosing, 12:158
  • neuropsychiatric side effects of, 20:238-239, 239t
  • P450 enzyme inhibitors and inducers, 11:149t, 150
  • serotonergic, 12:155
  • with similar appearance, 11:147-148, 148t
  • with similar names, 11:147-148, 148t
  • for VTE, 16:192-193

Drug screens, 12:157

Duty, 536Z:2-3

DVT. See Deep venous thrombosis

E

Early discharge criteria, 15:182

Echocardiography

  • in AF, 18:216
  • in heart failure, 7:90
  • for venous thromboembolism, 14:169

Ectopic pregnancy, 1:4-5

  • delayed or missed diagnosis of, 1:5t
  • risk factors for, 1:4t

Education

  • anticoagulation therapy, 15:180-181
  • intimate partner violence, 535Z:4
  • polypharmacy self-education, 12:156-157

Efavirenz, 538Z:6t

Eikenella corrodens, 25:309, 26:324

Elderly

  • adverse drug effects in, 11:147, 147t
  • CAP in, 9:112t
  • DVT prophylaxis in, S02101:3t
  • hyperthyroidism in, Geriatric 2:1-10, 10t
  • hypothyroidism in, Geriatric 2:1-10
  • initial trauma management in, Trauma 3:9-10
  • lower GI bleeding in, Geriatric 1:1-11, 2t
  • pain control in, 5:65-66
  • polypharmacy in, 11:145-150, 12:153-159
  • vulnerability to polypharmacy, 11:147-148

Electrical cardioversion

  • considerations for, 19:223-224
  • pharmacologically augmented, 19:224

Electrocardiography, 7:88

  • findings in AF, 18:215-216, 216t, 217f
  • with venous thromboembolism, 14:168

Electrolytes, 20:239-241, 239t

Embolism, pulmonary

  • diagnosis of, 14:171
  • diagnostic algorithm for, 14S
  • differential diagnosis of, 14:166t, 167
  • pre-test probability for, 14:167, 167t

EMLA (eutectic mixture of local anesthetics) cream, 22:267, 268t

Enalapril, 8:96t

Endocardial radiofrequency catheter ablation, 19:228

Endocarditis, bacterial, 20:241-242

Endocrinology, 20:239-241, 239t

Endometriosis, 1:12-13

Endophthalmitis, 13:172

Enoxaparin

  • for DVT prophylaxis, 10:141-142, 16:193, 195f, S02101:3t, 5-6, 6-7
  • PRIME study group, 16:197-199, S02101:5-6
  • PRINCE study, 16:197, S02101:5
  • for VTE prevention, 16:197t, 199

Enterobacter

  • in animal bites, 26:324
  • in prostatitis, 3:35

Enterococcus

  • in cholecystitis/cholangitis, 17:205t
  • in UTI and pyelonephritis, 1:10

Enzathine penicillin, 6:77t

Epididymis, appendix, torsion of, 2:24-25

Epididymitis, acute, 2:20t, 23-24

Epidural catheters, 5:64

Epinephrine

  • bupivacaine with, 26:318t
  • LET solution or gel, 22:268t, 269
  • lidocaine with, 26:318t
  • procaine with, 26:318t

Episcleritis, 13:172

Erythrocyte sedimentation rate, Geriatric 2:2

Erythromycin

  • for CAP, 9:112t, 113t, 114t, 10:139, 139t, 140t
  • for cervicitis, 1:10t
  • for chlamydia, 6:77t
  • daily cost, 9:117t
  • digoxin interactions, 12:155
  • ophthalmic ointment, 13:168t
  • warfarin interactions, 12:154, 155t

Escherichia coli

  • in acute epididymitis, 2:24
  • antimicrobial therapy for, 9:120
  • in cholecystitis/cholangitis, 17:205, 205t
  • in Fournier’s gangrene, 3:34
  • in gallbladder disease, 17:207
  • monotherapy vs. combination therapy for, 10:132
  • in PID, 1:9
  • in prostatitis, 3:35
  • in UTI and pyelonephritis, 1:10

Esmolol

  • for rate control in AF, 19:220, 222t
  • for SVT, 4:49, 4S
  • or thyroid storm, Geriatric 2:9, 9t

Ethacrynic acid, 8:98t

Ethical issues, 537Z:1-9

Ethicon, 26:321

Etodolac, 5:57, 57t

Etomidate

  • for adult sedation and analgesia, 21:253t
  • cost of, 21:258t
  • for procedural sedation, 21:250-251

Eutectic mixture of local anesthetics (EMLA) cream, 22:267, 268t

Evidence collection, 6:74-75

Exercise-induced AF, 19:227-228, 228t

Experts, qualification of, 536Z:3-4

Extensor tendons, 23:277

  • injuries of, 24:292t, 293-294
  • insertions in finger, 23:277, 280f
  • zones of, 23:276, 278f, 24:293, 293f

Extracorporeal shock wave lithotripsy, 17:209

Eye

  • examination of, 13:163-166
  • gross anatomy of, 13:163, 165f
  • red, 13:171-173

Eye injuries

  • non-traumatic, 13:170-171
  • traumatic, 13:166-170

Eyelid lacerations, 13:167

F

Facial fractures, 13:166-167

Famciclovir, 6:77t

Fasting, 21:258-259, 259t

"Fast Track" drugs, 11:148

Fear of anthrax, 12S:1-3

Felon, 25:304-305, 306f

Fenoprofen, 5:58

Fentanyl (Sublimaze)

  • for adult sedation and analgesia, 21:253t
  • cost of, 21:258t
  • for pain management, 5:62
  • for pediatric sedation and analgesia, 21:255t
  • for procedural sedation, 21:252-257

Fever (and a chill), 20:241-242

Fibroids, uterine, 1:13

Fight bites, 25:305t, 309, 26:324

Fingers

  • collateral ligaments surrounding joints of, 23:276, 277f
  • extensor tendon insertions in, 23:277, 280f
  • flexor digitorum profundus tendon insertions in, 23:276-277, 279f
  • flexor digitorum superficialis tendon insertions in, 23:276-277, 279f

Fingertip amputations, 24:297, 297f, 298f

Flecainide

  • for cardioversion, 19:222, 223, 223t, 225
  • for left ventricular hypertrophy, 19:227, 228t
  • for neurogenic AF, 19:227, 228t
  • for rate control, 19:220
  • for sinus rhythm maintenance, 19:226

Flexor digitorum profundus tendon, 23:276-277, 279f

Flexor digitorum superficialis tendon, 23:276-277, 279f

Flexor tendons, 23:276-277

  • injuries of, 24:292t, 294-295
  • pulleys of, 23:277, 279f
  • sheaths and bursae of, 23:277, 280f, 25:307f
  • zones of, 23:276, 278f, 24:295, 295f

Flexor tenosynovitis, 25:305

Fluconazole, 12:155t

Fluid resuscitation

  • delayed, Trauma 3:8
  • initial phase, Trauma 3:1-10

Flumazenil (Mazicon), 21:257-258

  • for reversal of adult sedation, 21:254t
  • for reversal of pediatric sedation, 21:256t

Fluoroquinolones

  • for CAP, 9:113t, 114t, 10:132, 138, 139, 139t, 140t
  • extended spectrum, 10:133-136
  • and methicillin-resistant S. aureus (MRSA), 10:135
  • over-extended spectrum of coverage, 10:134-135
  • for pyelonephritis, 1:11
  • resistance to, 9:117-118, 10:134-135
  • selective use of, 10:135-136
  • for urethritis, 3:37

Fluoxetine, 12:155

Flurbiprofen, 5:56t

Foley catheter

  • non-deflating, 3:37
  • placement of, 3:36, 36f

Foreign bodies

  • corneal, 13:167
  • in hand, 25:311
  • intraocular, 13:169
  • urethral, 3:37
  • in wounds, 26:318

Forensics

  • bioterrorism, 9S:4
  • specialized techniques for sexual abuse, 6:72-73

Forrester classification, 7:85, 85t

Fosphenytoin, 5:63

Fossa navicularis, 6:73

Fournier’s gangrene, 3:33-34

Fractures

  • of acetabulum, Trauma 4:9-10
  • Bennett’s, 24:289t
  • of distal phalanx, 24:287-288
  • distal tuft, 24:289t
  • facial, 13:166-167
  • of hand, 24:287-290, 289t
  • metacarpal (digits 2-5), 24:289-290, 289t
  • pelvic, Trauma 4:1-10
  • penile, 3:34
  • proximal and middle phalanx, 24:288-289, 289t
  • Rolando’s, 24:289t
  • terminology for, 24:289t
  • thumb, 24:289t, 290

Francisella tularensis, 10:138

Furosemide

  • for acute heart failure, 8:98t
  • for acute pulmonary edema, 8:95
G

Gabapentin, 5:63

Gallbladder disease

  • clinical manifestations of, 17:205, 206t
  • evaluation of, 17:206, 207t

Gamekeeper’s thumb, 24:292

Gangrene, Fournier’s, 3:33-34

Gardnerella vaginalis, 1:9

Garlic, 12:155t

Gastric vascular anomalies, Geriatric 1:10

Gastrointestinal bleeding

  • lower, in elderly, Geriatric 1:1-11, 2t
  • acute, Geriatric 1:5f, 6t
  • causes of, Geriatric 1:4-10, 4t
  • sources of, Geriatric 1:7t
  • upper, in elderly
  • acute, Geriatric 1:5f
  • sites of, Geriatric 1:8

Gastrointestinal function, 11:149

Gatifloxacin, 10:134

  • for CAP, 9:112t, 113t, 114t, 10:137t, 139t, 140t

Genitalia, male, 6:73t

Gentamicin

  • for acute bacterial prostatitis, 3:35
  • for acute cholangitis, 17:207, 208t, 209
  • ophthalmic ointment, 13:168t
  • ophthalmic solution, 13:168t

Geriatric patients. See Elderly

Giant cell arteritis, 13:175

Ginkgo biloba, 12:155t

Glaucoma, 13:172-173

Globe luxation, 13:170

Globe rupture, 13:169

Glucocorticoids, Geriatric 2:9, 9t

Glues, cyanocrylate, 13:169

Glycopyrrolate, 17:208

GnRH analogs, 1:13

Gonorrhea. See Neisseria gonorrhea

Guanethidine, Geriatric 2:9

H

Haemophilus influenzae

  • advanced generation macrolides for, 9:122
  • antimicrobial therapy for, 9:119, 120
  • combination therapy for, 9:123, 10:132
  • empiric antibiotic coverage for, 10:136
  • outpatient management of, 10:130, 131
  • in PID, 1:9
  • in pneumonia, 10:136, 138

Haldol. See Haloperidol

Haloperidol (Haldol), 21:255t, 258

Hand

  • acute, 23:275-283, 24:287-299, 25:303-311
  • amputated, replantation of, 24:296, 298t
  • anatomy of, 23:276-279
  • cleaning, 23:282
  • dislocations of, 24:290-291
  • fractures of, 24:287-290, 289t
  • human bites to, 26:325t
  • intrinsic muscles of, 23:277
  • mangled, 24:298-299
  • tendon injuries, 24:292-295
  • traumatic amputations of, 24:296-297
  • trauma to, 24:287-290

Hand cellulitis, 25:306

Hand infections, 25:303-308

  • danger signs, 25:303, 305t
  • deep space, 25:307-308, 308f
  • mimics, 25:303-304

Hand injuries

  • bites, 25:309-310
  • high-pressure injection injuries, 25:310-311
  • neurovascular, 24:295-296

Hand problems, 25:309-311

  • foreign bodies, 25:311
  • pediatric, 25:308-309

Head injury, closed, Trauma 3:9

Heart

  • in hypothyroidism, Geriatric 2:3
  • in thyrotoxicosis, Geriatric 2:7

Heart failure

  • ACC/AHA classification of, 7:89t
  • acute
  • diuretics for, 8:98t, 99
  • inotropic therapy for, 8:102, 103t
  • anticoagulation for, 8:104
  • chronic systolic
  • ACEIs/ARBs for, 8:96-97, 97t
  • beta-blockers for, 8:97-98, 97t
  • clinical pathophysiology of, 7:84-85
  • clinical presentation of, 7:83
  • congestive, 19:227, 228t
  • decompensated, 7:86-87, 8:105
  • acute, 7:81-91, 86f, 8:93-105
  • causes of, 7:87t
  • diagnosis of, 7:87
  • management strategies for, 8:95-96
  • precipitants of, 7:88t
  • definitions and categories of, 7:83-84
  • diagnosis of, 7:87t, 88
  • diastolic, 7:83t, 84
  • differential diagnosis of, 7:87-88, 90t
  • DVT prevention in, 7S, 8S
  • ECG, 7:88
  • etiologies of, 7:84, 84t
  • Forrester classification of, 7:85, 85t
  • history, 7:88
  • indications for admission to cardiac ICU, 8:105t
  • initial stabilization measures, 8:93-95
  • inpatient therapy for, 8:104
  • laboratory evaluation of, 7:88-89
  • management strategies for, 8:95-96
  • NYHA classification of, 7:88t
  • outpatient therapy for, 8:104
  • parameters of, 7:91t
  • patient disposition in, 8:105
  • pharmacotherapeutic strategies for, 8:96-100
  • physical examination of, 7:88
  • portable CXR findings in, 7:91t
  • prevention of DVT in, S02101:1-7
  • prevention of VTE in, S02101:7
  • radiographic modalities in, 7:90-91
  • systolic vs. diastolic, 7:83-84
  • therapeutic approaches to be avoided in, 8:104-105
  • vasodilators for, 8:100, 100t
  • without signs of shock, 8:96

Helical computerized tomography, 14:169

Hemodynamic status, 7:87t

Hemorrhage

  • physiology of, Trauma 3:5-6
  • retrobulbar, 13:170
  • subconjunctival, 13:167
  • vitreous, 13:173

Heparin

  • for AF, 19:222
  • for DVT, 15:177-178
  • low-molecular-weight (LMWH)
  • indications for, 15:177-178
  • interchangeability of, 15:184-185
  • for VTE prophylaxis, 15:182-183, 16:199-200, S02101:7
  • mechanism of action, 15:177
  • pharmacokinetics, 15:177
  • side effects of, 15:184
  • structure of, 15:177
  • unfractionated (UFH)
  • for DVT prophylaxis, S02101:6-7
  • limitations of, 15:181, 182t, 16:193, 194t
  • for VTE prevention, 15:181-182, 16:197t, 199
  • weight-based dosing of, 15:181, 181t

Heparin-induced thrombocytopenia, 15:183-184

Hepatic function, 11:149

Hepatitis B, 6:77t

Hepatitis B immune globulin, 6:77t

Herpes simplex virus, 6:77t

High-pressure injection injuries, 25:310-311

High-risk patients

  • medical malpractice and, 536Z:1-7
  • presentations, 536Z:5-7

HIV infection, 538Z:1-6

  • epidemiology of, 538Z:1
  • mucocutaneous exposure to, 538Z:5, 5t
  • percutaneous exposure to, 538Z:5, 5t
  • post-exposure evaluation and management of, 538Z:4-6
  • post-exposure prophylaxis of, 538Z:6, 6t
  • primary, 538Z:3
  • prophylaxis of, 6:77t, 538Z:6, 6t
  • resources, 538Z:7t
  • risk factors after occupational percutaneous exposure, 538Z:2, 3t
  • risk per exposure period, 538Z:2, 2t
  • transmission of, 538Z:1-3
  • treatment of, 6:77t

Hordeolum, 13:170-171

Hormonal therapy, 1:13

Hospital-based management

  • anticoagulation, 8:104
  • of CAP, 9:113t, 114t, 115-116, 10:131-133, 140t
  • antibiotic selection for, 9:116-117
  • antimicrobial treatment guidelines for, 10:129-142
  • combination therapy for, 9:123
  • guidelines for, 9:109-122, 10:137t, 139t
  • of DVT, 15:179-181
  • DVT prevention in, S02101:6-7
  • DVT risk factors for, S02101:1, 3t
  • of human bites to hand, 26:325t

Human bites, 25:309-310, 26:324, 325t

Human diploid cell vaccine (HDCV), 26:325

Human papilloma virus, 6:77t

Human tetanus immunoglobulin (HTIG), 26:323

Huntington’s disease, 20:243

Hydralazine/isosorbide dinitrate (ISDN), 8:102

Hydrocele/varicocele, acute, 2:25

Hydrocortisone, Geriatric 2:9t

Hydromorphone

  • for pain management, 5:62
  • starting dose, 5:61t

Hydroxyzine, 5:59

Hymen, 6:73

Hypercalcemia, 20:240

Hypercortisolemia, 20:241

Hypertensive retinopathy, 13:175

Hyperthermia, 20:242

Hyperthyroidism, 20:240-241, Geriatric 2:5-10

  • in elderly, Geriatric 2:1-10, 10t
  • laboratory testing in, Geriatric 2:7
  • physical findings in, Geriatric 2:6-7
  • signs and symptoms of, Geriatric 2:7t

Hypertonic saline, Trauma 3:8

Hyphema, 13:169-170

Hypnotic drugs, 21:248

Hypokalemia, 20:240

Hypotension, 8:101t

Hypothermia, 20:242

Hypothyroid crisis, Geriatric 2:3-4, 4t

Hypothyroidism, 20:240, Geriatric 2:2-5

  • admission criteria for, Geriatric 2:5, 5t
  • diagnosis of, Geriatric 2:2
  • in elderly, Geriatric 2:1-10
  • heart in, Geriatric 2:3
  • laboratory testing for, Geriatric 2:3, 4
  • physical examination in, Geriatric 2:2-3
  • signs and symptoms of, Geriatric 2:2, 3t
I

Ibuprofen, 5:56t

  • for pain management, 5:58

Ibutilide

  • for cardioversion, 19:223, 223t, 224
  • for rate control, 19:220
  • for SVT, 4S

IDSA. See Infectious Disease Society of America

Imipenem

  • for acute cholangitis, 17:208t
  • for CAP, 9:112t, 113t, 119, 10:137t, 139t

Imiquimod, 6:77t

Implanted analgesia devices, 5:64

Inappropriate care requests, 537Z:6

Inapsine. See Droperidol

Indinavir, 538Z:6t

Indomethacin, 5:57

  • for pain management, 5:57t

Infants, 2:24. See also Pediatric patients

Infection

  • animal bite wounds with increased risk for, 26:325t
  • deep space, 25:307-308
  • DVT prophylaxis in, S02101:3t
  • hand, 25:303-308
  • HIV, 538Z:1-6
  • urinary tract, in women, 1:10-11

Infection control, 12S:3-4

Infectious diarrhea, Geriatric 1:9

Infectious Disease Society of America (IDSA), guidelines for antimicrobial therapy of CAP, 9:113t, 10:138

Inflammatory bowel disease, idiopathic, Geriatric 1:8-9

Informed consent, 537Z:1-3, 3-4

Injury

  • avulsion, to pelvis, Trauma 4:8-9
  • bite, 25:309-310
  • clenched-fist, 26:324
  • closed head, Trauma 3:9
  • deep tissue, of hand, 25:303-311
  • extensor tendon, 24:292t, 293-294
  • eye, non-traumatic, 13:170-171
  • eye, traumatic, 13:166-170
  • flexor tendon, 24:292t, 294-295
  • high-pressure injection, 25:310-311
  • missed orthopedic, 536Z:6-7
  • neurovascular hand, 24:295-296
  • with pelvic fracture, Trauma 4:6, 6t
  • spinal cord, Trauma 3:9
  • tendon, 24:292-293, 292t
  • zipper injuries, 3:33

Inotropic therapy, 8:102-105, 103t

Inpatient therapy. See Hospital-based management

Intensive care unit, treatment of CAP in, 9:113t, 114t, 10:139t, 140t

Internet drug information resources, 12:157t

Internuclear ophthalmoplegia, 13:175

Intimate partner violence, 535Z:1-5

  • ED protocol for, 535Z:4, 4t
  • education, 535Z:4
  • interventions for, 535Z:3
  • mandatory reporting of, 535Z:4-5, 5t
  • presentation to ED, 535Z:2-3
  • risk factors for, 535Z:1-2
  • scope of the problem, 535Z:1
  • screening and assessment of, 535Z:3

Intraocular foreign bodies, 13:169

Intrascrotal appendages, 2:24-25, 24f

Intubated patients, 9:114t, 10:140t

Iodides, Geriatric 2:9t

Iodine, 19:227

Iontophoresis, 22:268t, 269

Iopanoic acid (Telepaque)

  • for thyroid storm, Geriatric 2:9
  • for thyrotoxicosis, 19:227

Ipodate (Oragrafin), Geriatric 2:9

Iridodialysis, 13:170

Ischemic colitis, Geriatric 1:6-7

Ischemic heart disease/myocardial infarction, 19:227, 228t

Isosorbide dinitrate (ISDN), 8:102

Itraconazole, 12:155t

K

Kentucky, 535Z:5t

Keratitis, bacterial, 13:171-172

Ketalar. See Ketamine

Ketamine (Ketalar)

  • contraindications to, 21:250, 251t
  • cost of, 21:258t
  • for dissociation, 21:254t
  • for procedural sedation, 21:250
  • for sedation of ventilated patients, 22:266

Ketoconazole, 12:155t

Ketoprofen, 5:56t

  • for pain management, 5:58

Ketorolac, 5:57t

  • for pain management, 5:58

Kidney stones, 1:11-12

Klebsiella

  • in acute epididymitis, 2:24
  • antimicrobial therapy for, 9:120
  • in CAP, 10:138
  • in cholecystitis/cholangitis, 17:205t
  • in gallbladder disease, 17:207
  • monotherapy vs. combination therapy for, 10:132
  • in prostatitis, 3:35
  • in UTI and pyelonephritis, 1:10
L

Labeled RBCs, Geriatric 1:10

Labial separation, 6:72, 74f

Labial traction, 6:72, 74f

Labia majora, 6:73

Labia minora, 6:73

Lacerations, 26:316

  • corneal, 13:169
  • eyelid, 13:167

Lamivudine, 538Z:6t

Langer’s lines, 26:317, 317f

Laser, 6:77t

Laws addressing mandatory reporting of intimate partner violence, 535Z:5t

Lawsuits, 536Z:4-5

Left atrial appendage flow, 18:214-215

Left ventricular dysfunction, 19:227, 228t

Left ventricular hypertrophy, 19:227, 228t

Legal issues, 536Z:1-2

  • considerations for adverse drug effects, 12:156
  • lawsuits, 536Z:4-5
  • mandatory reporting of intimate partner violence, 535Z:4-5, 5t
  • medical malpractice, 536Z:1-7
  • in pediatric sexual abuse, 6:76

Legionella

  • antimicrobial therapy for, 9:119, 120
  • in CAP, 10:136, 138

Legionella pneumophila

  • combination therapy for, 9:123, 10:132
  • outpatient management of, 10:130, 131

Lens dislocation/subluxation, 13:170

LET (lidocaine, epinephrine, tetracaine) solution or gel, 22:268t, 269

Levofloxacin, 10:134

  • for CAP, 9:112t, 113t, 114t, 10:132, 133, 137t, 139t, 140t
  • daily cost, 9:117t
  • resistance to, 10:134

Levorphanol, 5:61t

Lewisite, 2S:3

Lidocaine (Xylocaine)

  • EMLA cream, 22:267, 268t
  • with epinephrine, 26:318t

LET solution or gel, 22:268t, 269

  • for pain management, 5:63-64
  • for priapism, 3:30
  • topical, 5:63-64
  • for wound management, 26:318-319, 318t

Limbic encephalitis, 20:243

Lisinopril, 8:96t

Lithium

  • NSAID interactions, 12:155
  • for thyroid storm, Geriatric 2:9, 9t
  • for thyrotoxicosis, 19:227

LMWH. See Heparin, low-molecular-weight

Local anesthetics, 26:318, 318t

Lorazepam (Ativan)

  • for adult sedation and analgesia, 21:253t
  • for procedural sedation, 21:252
  • for sedation of ventilated patients, 22:266

Losartan, 8:96t

Lower GI bleeding, Geriatric 1:1-11, 2t

  • acute
  • final diagnosis in, Geriatric 1:6t
  • stratification of patients presenting with, Geriatric 1:5f
  • causes of, Geriatric 1:4-10, 4t
  • diagnostics, Geriatric 1:10

Lugol’s iodine

  • for thyroid storm, Geriatric 2:9, 9t
  • for thyrotoxicosis, 19:227

Luxation, globe, 13:170

Lyme disease, 20:242

M

Macrolides

  • advanced generation, 9:122-123
  • for CAP, 9:113t, 114t, 10:131-132, 132, 137t, 138, 139, 139t, 140t

Male patients

  • genital development, 6:73t
  • urologic emergencies, 2:17-26, 3:29-38
  • urologic examination, 2:18-19

Mallet finger deformity, 24:293-294, 293f

Malpractice, medical, 536Z:1-7

Mandatory reporting of intimate partner violence, 535Z:4-5, 5t

Mangled hand, 24:298-299

Manual detorsion of testicular torsion, 2:23, 23f

Manual reduction of paraphimosis, 3:32-33, 33f

Marcaine. See Bupivacaine

Maze procedure, 19:228

Mazicon. See Flumazenil

Meckels’ diverticulum, Geriatric 1:10

MEDENOX trial, 10:141-142, 16:195, S02101:4-5

  • results, 16:197, S02101:5
  • study design, 16:195-197, S02101:4-5

Medical malpractice, 536Z:1-7

  • common law, 536Z:2-3
  • relevant statutes, 536Z:3-4

Medical practice skills, 536Z:4-5

Medications. See Drugs; Over-the-counter (OTC) medications

Meningitis, 20:241-242, 536Z:7

Meperidine (Demerol), 17:208

  • for adult sedation and analgesia, 21:253t
  • for biliary disorders, 17:208
  • for pain management, 5:61
  • for procedural sedation, 21:249, 252
  • serotonergic drug interactions, 12:155
  • starting dose, 5:61t

Mesenteric vascular insufficiency, Geriatric 1:7-8

Metacarpal fractures (digits 2-5), 24:289-290, 289t

Metaxalone, 5:62t

Methadone, 5:61, 61t

Methicillin-resistant Staphylococcus aureus (MRSA), 10:135

Methimazole

  • for thyroid storm, Geriatric 2:9, 9t
  • for thyrotoxicosis, 19:227

Methocarbamol, 5:62t

Methohexital (Brevital)

  • for adult sedation and analgesia, 21:253t
  • cost of, 21:258t
  • for pediatric sedation and analgesia, 21:255t
  • for procedural sedation, 21:252

Methotrexate, 1:5

Metoclopramide, 5:59

Metolazone, 8:98t

Metoprolol

  • for chronic systolic heart failure, 8:97t
  • for rate control in AF, 19:220, 222t

Metronidazole

  • for acute cholangitis, 17:207, 208t
  • for bacterial vaginosis, 6:77t
  • for CAP, 9:112t, 113t, 119-120, 10:137t, 139t
  • for trichomonas, 6:77t
  • warfarin interactions, 12:154, 155t

Midazolam (Versed)

  • for adult sedation and analgesia, 21:253t
  • cost of, 21:258t
  • for pediatric sedation and analgesia, 21:255t, 22:267
  • for procedural sedation, 21:252, 257
  • for sedation of ventilated patients, 22:266

Middle phalanx fractures, 24:288-289, 289t

Milrinone, 8:102t, 104

Minors, consent by, 537Z:4-5

Mirfentanil, 21:257

Mississippi, 535Z:5t

Modified Ramsay Score, 22:265

  • for procedural sedation, 22:267t

Monoamine oxidase inhibitors, 12:155

Monobactam, 9:119

Moraxella catarrhalis

  • antimicrobial therapy for, 9:120
  • in CAP, 10:138
  • combination therapy for, 9:123, 10:132
  • empiric antibiotic coverage for, 10:136
  • outpatient management of, 10:130, 131
  • in pneumonia, 10:136

Morphine

  • for adult sedation and analgesia, 21:253t
  • cost of, 21:258t
  • for heart failure, 8:102
  • for pain management, 5:60
  • for procedural sedation, 21:252
  • starting dose, 5:61t

Motor function evaluation, acute hand, 23:282

Moxifloxacin, 10:133-134

  • for CAP, 9:112t, 113t, 114t, 10:137t, 139t, 140t

MP joint dislocations, 24:292

MRI scans

  • lower GI, Geriatric 1:10
  • pediatric, 22:266-267

Multifocal atrial tachycardia (MAT), 4:43, 43f, 47t

Muscle relaxants, 11:150

Muscles, intrinsic hand, 23:277

Mustard (HD), 2S:3

Mycoplasma

  • antimicrobial therapy for, 9:119, 120
  • in PID, 1:9

Mycoplasma pneumoniae

  • in CAP, 10:136, 138, 139t
  • combination therapy for, 9:123, 10:132
  • empiric antibiotic coverage for, 10:136
  • outpatient management of, 10:130, 131

Myocardial decompensation, acute, 7:81-91

Myocardial infarction, 19:227, 228t

Myocardial injury, 7:84-85

Myxedema coma, Geriatric 2:3

  • clinical features of, Geriatric 2:4, 4t
  • precipitating events for, Geriatric 2:3-4, 4t
  • treatment of, Geriatric 2:4-5, 5t
N

Nabumetone, 5:57-58

  • for pain management, 5:57t

Nalbuphine, 5:61t

Nalmefene, 21:257

Naloxone (Narcan), 21:257

  • cost of, 21:258t
  • for reversal of adult sedation, 21:254t
  • or reversal of pediatric sedation, 21:256t

Naltrexone, 21:257

Naprosyn, 5:58

Naproxen, 5:58

Narcan. See Naloxone

National Committee on Clinical Laboratory Standards (NCCLS) year 2002 breakpoints, 9:118-119

  • outcome-effective strategies based on, 10:129-142

Natriuretic peptides

  • in AF, 18:214
  • B-type, 7:89-90

Nausea and vomiting, medication-induced, 5:59

NCCLS. See National Committee on Clinical Laboratory Standards

Necrotizing fasciitis, 25:306-307

Neisseria gonorrhoeae

  • in acute epididymitis, 2:24
  • prophylaxis of, 6:77t
  • treatment of, 1:10t, 6:77t
  • in urethritis, 3:37

Neisseria meningitidis, 10:138

Nelfinavir, 538Z:6t

Nerve agents, 2S:3

Nerves, hand, 23:278-279

Nesiritide, 8:100-101, 100t, 101t

Neurogenic AF, 19:227

Neuroleptic agents, 21:258

Neurological evaluation, of acute hand, 23:281-282

Neuroophthalmology, 13:174-175

Neurovascular injuries, to hand, 24:295-296

New Hampshire, 535Z:5t

New Mexico, 535Z:5t

New York Heart Association class, 7:88t

Nitrate therapy, 8:101t

Nitrofurantoin (Macrobid), 1:10-11

Nitroglycerin (NTG)

  • for acute pulmonary edema, 8:95
  • for heart failure, 8:100, 100t
  • with lower GI bleeding, Geriatric 1:10

Nitroprusside, 8:100, 100t

Nitrous oxide, 21:249-250

Non-steroidal anti-inflammatory drugs (NSAIDs)

  • contraindications to, 8:104-105
  • drug interactions, 12:155
  • for ectopic pregnancy, 1:5
  • for pain management, 5:55-58, 56t-57t
  • for uterine fibroids, 1:13
  • warfarin interactions, 12:154, 155t

Normeperidine, 5:61

Novocaine. See Procaine

NPO status, for children, 22:263-264, 264t

NSAIDs. See Non-steroidal anti-inflammatory drugs

NTG. See Nitroglycerin

Nursing homes, CAP in, 9:112t

Nursing issues in VTE prophylaxis, 16:199-200

O

Obesity, 15:184

Occupational percutaneous exposure to HIV, 538Z:2

Octylcyanoacrylate (Dermabond, Ethicon), 26:321

Ocular burns/chemical exposure, 13:168-169, 170t

Ocular manifestations of systemic disease, 13:175

Ofloxacin

  • for acute bacterial prostatitis, 3:35
  • for acute epididymitis, 2:24
  • for gonorrhea, 1:10t, 6:77t
  • ophthalmic solution, 13:168t
  • for pyelonephritis, 1:11

Ondansetron, 5:59

Ophthalmic antibiotics, 13:168t

Ophthalmologic emergencies, 13:163-175

Ophthalmologists, 13:175

Ophthalmoplegia, internuclear, 13:175

Opioids

  • analgesics, 17:208
  • antagonists, 21:257
  • for pain management, 5:58-62
  • for procedural sedation, 21:252-257
  • short-acting, 21:257
  • starting doses, 5:61t

Optic nerve trauma, 13:170

Optic neuritis, 13:175

Oragrafin. See Ipodate

Oral contraceptives, 1:13

Orbital cellulitis, 13:173

Orbital compartment syndrome, 13:170

Orchitis, 2:25

Orphenadrine, 5:62t

Orthopedic injury, missed, 536Z:6-7

Osteoporosis, heparin-induced, 15:184

Outpatient therapy

  • anticoagulation, 8:104
  • for CAP, 9:113t, 114t, 115-116, 10:140t
  • ASCAP consensus panel recommendations for, 10:130-131
  • guidelines for, 10:137t, 139t
  • for DVT, 15:179-181
  • minimal criteria for, 15:182
  • minimal criteria for early discharge, 15:183t
  • pharmacoeconomic considerations for, 15:180
  • for venous thromboembolism, 15:178-179

Ovarian cysts, 1:12

Ovarian torsion, 1:5, 6, 6f

Over-the-counter (OTC) medications, for pain management, 5:56t-57t

Oxaprozin, 5:56t, 58

Oxycodone, 5:61, 61t

Oxymorphone, 5:61t, 62

Oxyphenbutazone, 5:58

P

Pain

  • abdominal
  • high-risk patients, 536Z:6
  • right lower quadrant, in women, 1:1-13
  • acute, 5:64
  • associated with sources of GI bleeding, Geriatric 1:7t
  • chest, high-risk patients, 536Z:5-6
  • chronic, 5:64-65
  • definition and assessment of, 5:54

Pain management, 5:53-66

  • adjuvants, 5:62
  • in children, 5:65
  • in elderly, 5:65-66
  • general principles of, 5:65t
  • NSAIDs for, 5:55, 56t-57t
  • over-the-counter medications for, 5:56t-57t
  • relief of pain and suffering, 537Z:8-9
  • special considerations, 5:64-66

Pain pathway, 5:54-64

Paraphimosis, 3:32-33, 33f

Parents

  • inappropriate care requests, 537Z:6
  • permission, 537Z:4
  • refusal of treatment , overriding, 537Z:5-6

Parkinson’s disease, 20:242

Paronychia

  • acute, 25:304
  • technique for, 25:304, 306f

Paroxetine, 12:155

Pasteurella multocida, 25:309, 26:324, 325

Patient education

  • for anticoagulation therapy, 15:180-181
  • about intimate partner violence, 535Z:4
  • polypharmacy self-education, 12:156-157

Pediatric patients

  • advance directives, 537Z:5
  • drugs and reversal agents for sedation and analgesia in, 21:255t-266t
  • ethical issues, 537Z:1-9
  • hand problems in, 25:308-309
  • informed consent with, 537Z:3-4
  • initial trauma management in, Trauma 3:10
  • sedation of, 22:266-267
  • sexual abuse of, 6:69-76
  • definition of the problem, 6:70
  • evidence collection in, 6:74-75
  • history and interview, 6:71
  • legal issues and reporting, 6:76
  • physical examination findings and classification of, 6:74, 75t
  • presentation of, 6:70-71
  • terminology and anatomy of, 6:73-74

Pelvic fractures, adult, Trauma 4:1-10

  • classification of, Trauma 4:5-6
  • diagnostic adjuncts, Trauma 4:4
  • epidemiology of, Trauma 4:1
  • history, Trauma 4:3-4
  • physical exam with, Trauma 4:4
  • radiologic evaluation of, Trauma 4:4-5
  • resulting in ring disruption, Trauma 4:6-8
  • single bone and avulsion injuries, Trauma 4:8-9
  • Tile classification of, Trauma 4:5, 5t
  • transfer of patients with, Trauma 4:8
  • Young classification of, Trauma 4:6, 6t, 7f

Pelvic inflammatory disease, 1:9-10

  • diagnostic criteria for, 1:9t
  • outpatient treatment of, 1:9, 10t

Pelvis, Trauma 4:2-3

Penicillin

  • for CAP, 9:119
  • for conjunctivitis, 13:171

Penile cancer, 3:34

Penile disorders, 3:29-34

Penile fracture, 3:34

Penile tourniquet, 3:33

Penis, 3:31f

Pennsylvania, 535Z:5t

Pentazocine, 5:62

Pentobarbital (Nembutal)

  • cost of, 21:258t
  • for pediatric sedation and analgesia, 21:256t, 22:266-267

Peptostreptococcus, 1:9

Periorbital (preseptal)/orbital cellulitis, 13:173

Pharmacodynamics, 11:149-150

Pharmacoeconomics

  • in outpatient therapy for DVT, 15:180
  • in VTE prophylaxis, 16:199

Pharmacological cardioversion, 19:222-223, 224

Pharmacologically augmented electrical cardioversion, 19:224

Phenazopyridine, 1:11

Phenelzine, 12:155

Phenergan. See Chlorpromazine

Phenylbutazone, 5:58

Phenylephrine, 3:30

Phenytoin, 5:63

Pheochromocytoma, 20:241

Phimosis, 3:31-32

  • dorsal slit procedure for, 3:32, 32f
  • paraphimosis, 3:32-33

Phosgene (CG), 2S:3

Physical status, 21:249, 250t

Physiology, 11:148

Pinguecula/pterygium, 13:170

Piperacillin

  • for acute cholangitis, 17:208t
  • for CAP, 9:113t, 10:139t

Piperacillin-tazobactam, 9:113t, 10:139t

PIP joint dislocations, 24:291, 291f

Piroxicam, 5:57t, 58

Plain abdominal films, Geriatric 1:10

Planning for bioterrorism, 12S:4

Plasma, Trauma 3:7

Platelets, Trauma 3:7

Pneumonia, community-acquired (CAP)

  • antibiotic therapy for
  • consensus guidelines for, 10:138-139
  • empiric, 10:136-138
  • selection for hospitalized patients, 9:116-117, 10:129-142
  • antimicrobial therapy for, 9:119-120, 10:129-142
  • empiric, 9:112t, 113t, 10:137t
  • guidelines for, 9:112t, 113t, 10:139t
  • ASCAP 2002 Consensus Report Panel and Scientific Roundtable, 9:111
  • ASCAP 2002 guidelines, 9:112t
  • combination therapy for, 9:123, 10:131-133
  • critical pathways and protocols for, 10:132
  • diagnosis of, 9:111-115
  • empiric therapy for, 9:114t, 10:140t
  • epidemiology of, 9:111-115
  • evaluation of, 9:111-115
  • in-hospital management of, 9:109-122, 10:131-133, 137t, 139t
  • initial stabilization and adjunctive measures for, 9:113-115
  • outcome-effective strategies for, 9:109-122
  • outcome-optimizing regimens for, 9:121-122
  • outpatient management of, 9:115-116, 10:130-131
  • ASCAP consensus panel recommendations for, 10:130-131
  • guidelines for, 10:137t, 139t
  • pathogens in, 10:138
  • patient disposition in, 9:115
  • patient management recommendations, 10:130-131
  • prevention of DVT in, 10:139-142
  • prognostic scoring for, 9:115-116
  • signs and symptoms of, 9:113
  • treatment guidelines for, 9:120-121

Podofilox, 6:77t

Podophyllin, 6:77t

Polypharmacy

  • in elderly, 11:145-150, 12:153-159
  • etiology of, 11:147
  • high-risk drugs, 12:153-155, 155t
  • legal considerations for, 12:156
  • scope of the problem, 11:146-147
  • self-education, 12:156-157
  • strategies to prevent ADEs, 12:157t
  • vulnerability of elderly to, 11:147-148

Polyps, colonic, Geriatric 1:9

Porphyria, acute intermittent, 20:242

Portable CXR, 7:91t

Potassium iodide, saturated solution of (SSKI)

  • for thyroid storm, Geriatric 2:9, 9t
  • for thyrotoxicosis, 19:227

Prazosin, 12:156t

Pregnancy, ectopic, 1:4-5

  • delayed or missed diagnosis of, 1:5t
  • risk factors for, 1:4t

Preseptal/orbital cellulitis, 13:173

Priapism, 3:29-31

Prilocaine, 22:267, 268t

PRIME study group, 16:197-199, S02101:5-6

PRINCE study, 16:197, S02101:5

Procainamide

  • for cardioversion, 19:222, 223, 223t, 225
  • for post-surgical AF, 19:227, 228t
  • for rate control in AF, 19:220, 222t
  • for SVT, 4S
  • for WPW syndrome, 19:227, 228t

Procaine (Novocaine), 26:318t

Procaine with epinephrine, 26:318t

Prochlorperazine, 5:59

Proctitis, radiation, Geriatric 1:9

Promethazine (Thorazine), 17:208, 21:249

Prone knee-chest position, 6:72, 74f

Propafenone

  • for cardioversion, 19:222, 223, 223t, 225
  • for exercise-induced AF, 19:227-228, 228t
  • for left ventricular hypertrophy, 19:227, 228t
  • for rate control, 19:220
  • for sinus rhythm maintenance, 19:226

Propofol (Diprivan)

  • for adult sedation and analgesia, 21:254t
  • cost of, 21:258t
  • for procedural sedation, 21:251
  • for sedation of ventilated patients, 22:266

Propoxyphene, 5:61-62

Propranolol, Geriatric 2:9, 9t

Propylthiouracil

  • for thyroid storm, Geriatric 2:9, 9t
  • for thyrotoxicosis, 19:227

Prostate, 3:34-35

Prostate cancer, 3:35

Prostatitis, 3:34-35

Proteus

  • monotherapy vs. combination therapy for, 10:132
  • in prostatitis, 3:35
  • in UTI and pyelonephritis, 1:10

Proximal and middle phalanx fractures, 24:288-289, 289t

Pseudoephedrine, 3:30

Pseudomonas

  • in acute epididymitis, 2:24
  • antibiotic coverage for, 10:136
  • antimicrobial therapy for, 9:119, 120, 10:137t
  • in gallbladder disease, 17:207
  • monotherapy vs. combination therapy for, 10:132
  • in prostatitis, 3:35
  • in UTI and pyelonephritis, 1:10

Pseudotumor cerebri, 13:175

Psychiatric complaints

  • incorrect assumptions and pitfalls, 20:234-235, 235t
  • medical conditions presenting with, 20:242-243, 242t
  • organic and medical mimics, 20:233-234, 236-238
  • ABC mnemonic for, 20:236-238, 237t
  • clues to help differentiate, 20:235, 236t

Pterygium, 13:170

Pubic hair, 6:73t

Publication resources, 12:157t

Pulmonary agents, 2S:3

Pulmonary angiography, 14:170

Pulmonary aspiration, 21:258-259, 259t

Pulmonary edema, acute, 7:85-86, 8:105

  • diagnosis of, 7:85-86, 87t
  • initial therapy for, 8:95, 95t
  • management strategies for, 8:95

Pulmonary embolectomy, 15:186

Pulmonary embolism

  • D-dimer test for, 14:170f, 171
  • diagnosis of, 14:171, 14S
  • differential diagnosis of, 14:166t, 167
  • pre-test probability for, 14:167, 167t
  • prevention of, S02101:1-7
  • treatment of, 15:175-186

Puncture wounds, 26:316

Pyelonephritis, 1:10-11

Q

Qualification of experts, 536Z:3-4

Quality assurance, 22:270-271, 271f

Quality improvement, 21:258-259

Quinidine

  • for cardioversion, 19:222, 223t, 225
  • CCB interactions, 12:156t
  • digoxin interactions, 12:155
  • for neurogenic AF, 19:227, 228t

Quinolones, 9:112t, 119, 10:136

R

Rabies immune globulin (RIG), 26:325

Rabies prophylaxis, 26:325, 325t

RADAR screening, 535Z:3

Radiation proctitis, Geriatric 1:9

Radiofrequency catheter ablation, endocardial, 19:228

Radiography

  • chest (CXR)
  • in heart failure, 7:90, 91t
  • portable, 7:91t
  • in venous thromboembolism, 14:167-168
  • cleaning, 23:282-283
  • of hand, 23:282-283
  • in heart failure, 7:90-91
  • of pelvic fracture, Trauma 4:4-5
  • plain abdominal films, Geriatric 1:10

Ramipril, 8:96t

Ramsey Sedation Scale, 21:258-259, 258t. See also Modified Ramsay Score

Rapifentanil, 21:257

Rectal ulcers, Geriatric 1:9

Red blood cells, labeled, Geriatric 1:10

Red eye, 13:171-173

Refusal of treatment, parental, 537Z:5-6

Relief of pain and suffering, 537Z:8-9

Remifentanil, 21:257

Renal function, 11:149

Renal insufficiency, heparin-induced, 15:184

Reporting adverse drug events, 12:159

Reporting intimate partner violence, 535Z:4-5, 5t

Reporting pediatric sexual abuse, 6:76

Requests for inappropriate care, 537Z:6

Reserpine, Geriatric 2:9, 9t

Resources

  • for drug information, 12:157t
  • HIV-related, 538Z:7t

Respiratory failure, S02101:3t

Resuscitation, Trauma 3:2-5

  • barrier precautions, Trauma 3:5
  • endpoints of, Trauma 3:8-9
  • horizontal, Trauma 3:3, 4f
  • paradigms of, Trauma 3:3
  • termination of efforts, 537Z:8

Resuscitation fluid, Trauma 3:6-8

Resuscitation physicians, Trauma 3:2-3

Retinal detachments, 13:173

Retinitis, CMV, 13:175

Retinopathy

  • diabetic, 13:175
  • hypertensive, 13:175

Retrobulbar hemorrhage, 13:170

Rhode Island, 535Z:5t

RIG. See Rabies immune globulin

Right lower quadrant abdominal pain, in women

  • algorithmic approach to, 1:1-13
  • differential diagnosis of, 1:2t, 3f, 4-13

Rights, children’s, 537Z:1-9

Ring disruption, pelvic fractures resulting in, Trauma 4:6-8

Rofecoxib, 5:57t, 58

Rolando’s fractures, 24:289t

RU-486, 1:13

S

Sacroiliac complex

  • anatomy of, Trauma 4:2-3
  • mechanical design of, Trauma 4:2-3, 3f
  • posterior view of, Trauma 4:2f
  • sagittal view, Trauma 4:3

Salicylates, 12:155t

Saline, hypertonic, Trauma 3:8

Saline, swab, and Foley catheter techniques for sexual abuse examination, 6:72

Sarin (GB), 2S:3

Scleritis, 13:172

Scopolamine

  • drug interactions, 11:150
  • for pain management, 5:59

Screening

  • for domestic violence, 535Z:3
  • for VTE, 16:192-193

Scrotal disorders, 2:19-20

Scrotum

  • acute, 2:19-20, 19t
  • anatomy of, 2:19, 19f
  • intrascrotal appendages, 2:24-25, 24f
  • trauma to, 2:26

Sedation

  • adult, drugs and reversal agents for, 21:253t-255t
  • adverse events, 22:269t, 270-271
  • agents for, 21:248-249, 249-258
  • complications of, 22:270-271
  • conscious
  • definition of, 21:248
  • sample discharge instructions form, 22:270f
  • deep, 21:248
  • dissociative, 21:248
  • exclusions, 21:249, 251t
  • fasting recommendations to reduce risk of pulmonary aspiration, 21:258-259, 259t
  • levels of, 21:248, 249t
  • monitoring, 22:265-266
  • for non-painful conditions, 22:266-267
  • patient assessment for, 21:248, 248t
  • patient selection for, 22:263-264
  • pediatric, 22:266
  • for CT and MRI scans, 22:266-267
  • drugs and reversal agents for, 21:255t-266t
  • post-procedure care, 22:269
  • post-sedation and analgesia discharge criteria, 22:269, 269t
  • preparation for, 22:264-265, 265t
  • pre-sedation assessment, 22:264-265
  • procedural, 21:247-259, 22:263-271
  • quality assurance, 22:270-271, 271f
  • quality improvement and monitoring, 21:258-259
  • Ramsey Scale, 21:258-259, 258t
  • reversal agents, 21:257
  • topical agents for, 22:267-269
  • unconscious, 21:248
  • for ventilated patients, 22:266
  • for wound management, 26:318-319

Sedatives, 21:249-258

  • classification of, 21:248-249
  • combination of, 21:257
  • cost of, 21:258t
  • definition of, 21:248

Selective serotonin-reuptake inhibitors

  • for pain management, 5:63
  • serotonergic drug interactions, 12:155

Self-education, 12:156-157

Sensation, in hand, 23:281-282

Septic arthritis, 25:305-306

Serotonergic drugs, 12:155

Serratia, 3:35

Sertraline, 12:155

Sexual abuse

  • behavioral indicators of, 6:70, 72t
  • complaint/exam indicators of, 6:70, 72t
  • differential diagnosis of, 6:75-76
  • examination of, 6:71
  • interview questions, 6:71, 73t
  • pediatric, 6:69-76
  • physical examination findings and classification of, 6:74, 75t
  • physical examination techniques for, 6:72
  • specialized forensic exam techniques, 6:72-73

Sexually transmitted diseases

  • prophylaxis of, 6:75, 77t
  • testing for, 6:75
  • treatment of, 6:77t

Shock

  • cardiogenic, 7:85, 8:105
  • diagnosis of, 7:85
  • diagnostic criteria for, 7:85t
  • etiologies of, 7:84, 84t
  • management strategies for, 8:95
  • physiology of, Trauma 3:5-6

Sigmoidoscopy, Geriatric 1:10

Sinus node reentrant tachycardia, 4:43, 47t

Sinus rhythm maintenance, 19:225-226

Sinus tachycardia, 4:42-43, 43f, 47t

Skeletal muscle relaxants, 5:62, 62t

Skin-closure tapes, 26:322

Small bowel vascular anomalies, Geriatric 1:10

Small intestinal ulceration, Geriatric 1:10

Smallpox infection control, 12S:3-4

Sodium sulfacetamide ointment, 13:168t

Sodium sulfacetamide solution, 13:168t

Software resources, 12:157t

Soman, 2S:3

SOS (Sick, Old, Surgery) DVT QuickSCREEN®, 16:193

Sotalol

  • for brady-tachy syndrome, 19:227, 228t
  • for cardioversion, 19:222, 223t, 225
  • for exercise-induced AF, 19:227-228, 228t
  • for ischemic heart disease/MI, 19:227, 228t
  • for rate control in AF, 19:220, 222t
  • for sinus rhythm maintenance, 19:226

Spectinomycin, 6:77t

Spinal cord injury, Trauma 3:9

Spironolactone, 8:99-100

Staff communication, 12:158

Stanford (CA) Hospital and Clinics (SHC) & Lucile Packard Children's Hospital (LPCH), 12S:4

Staphylococcus

  • in acute paronychia, 25:304
  • in animal bites, 25:309
  • in cholecystitis/cholangitis, 17:205, 205t
  • in conjunctivitis, 13:171

Staphylococcus aureus

  • in CAP, 10:138
  • combination therapy for, 9:123, 10:132
  • empiric antimicrobial therapy for, 10:137t
  • in fight bites, 25:309
  • methicillin-resistant (MRSA), 10:135

Staphylococcus saprophyticus, 1:10

Staples, 26:321-322

Statutes of limitation, 536Z:3

Stavudine, 538Z:6t

St. John’s wort, 12:155

Streptococcus

  • in animal bites, 25:309
  • in cholecystitis/cholangitis, 17:205, 205t
  • in conjunctivitis, 13:171

Streptococcus faecalis, 3:35

Streptococcus pneumoniae

  • antibiotic therapy for, 10:136
  • antimicrobial therapy for, 9:119, 120, 10:137t
  • in CAP, 10:136, 138, 139t
  • ceftriaxone vs. cefotaxime for, 9:122-123
  • combination therapy for, 9:121-122, 123, 10:132
  • fluoroquinolone resistance in, 9:117-118
  • outpatient management of, 10:130, 131
  • year 2002 NCCLS breakpoints, 9:118-119

Streptococcus pyogenes, 10:138

Streptokinase, 15:185, 185t

Stress counseling, 11S:1-4

Stroke

  • after AF, 18:213
  • risk factors for, 19:224t
  • source of, 18:216t

Subconjunctival hemorrhage, 13:167

Sublimaze. See Fentanyl

Subluxation, lens, 13:170

Sudden death, 8:105

Sudden visual loss, 13:173-174

Sufentanil, 21:257

Suffering, relief of, 537Z:8-9

Sulbactam

  • for acute cholangitis, 17:208t
  • for CAP, 9:112t, 113t, 10:137t, 139t

Sulfamethoxazole. See Trimethoprim/sulfamethoxazole (Bactrim)

Sulindac, 5:57, 57t

Supine frog leg position, 6:72

Supine knee-chest position, 6:72

Supportive services for patients, 12:158

Supraventricular tachycardia, 4:41-50

  • chronic management of, 4:50
  • classification of, 4:42, 42t
  • clinical presentation of, 4:42
  • hemodynamically stable, 4:46-48
  • hemodynamically unstable, 4:46
  • incidence and prevalence of, 4:41-42
  • management of, 4:46-50
  • pathophysiology of, 4:42-46
  • pharmacologic management of, 4:48-49, 4S
  • summary, 4:47t

Surgical treatment

  • of paraphimosis, 3:32-33, 33f
  • post-procedure care, 22:269
  • post-surgical AF, 19:227, 228t
  • pre-procedural airway examination, 22:264, 266t
  • pre-procedural assessment, 22:267t
  • pre-sedation assessment, 22:264-265
  • procedural sedation, 21:247-259, 22:263-271

Suture material, 26:322t

Sutures, 26:321t, 322t

Syphilis, 6:77t

Systemic lupus erythematosus, 20:242

T

T3, Geriatric 2:1-2

T4

  • free, Geriatric 2:1
  • total, Geriatric 2:1

Tabun (GA), 2S:3

Tachyarrhythmias

  • atrial, 4:42t
  • atrioventricular, 4:42t

Tachycardia, 4:42t

TAC (tetracaine/adrenaline/cocaine) solution or gel, 22:267-269, 268t

Tanner staging, 6:73t

Tazobactam

  • for acute cholangitis, 17:208t
  • for CAP, 9:112t, 113t, 10:137t, 139t

TCA. See Trichloroacetic acid

Telepaque. See Iopanoic acid

Tendon injuries

  • care of, 24:292-293, 292t
  • in hand, 24:292-295

Tenosynovitis, flexor, 25:305

Terbutaline, 3:30

Termination of resuscitation efforts, 537Z:8

Terminology

  • of fractures, 24:289t
  • of hand, 23:276

Testicular cancer, 2:26

Testicular torsion, 2:20-23, 21f

  • differential diagnosis of, 2:20-26, 20t
  • manual detorsion of, 2:23, 23f

Testis

  • anatomy of, 2:19, 19f
  • appendix, torsion of, 2:24-25
  • arterial signal to, 2:22, 22f
  • bell-clapper testicle, 2:20-21, 21f

Tetanus, 26:323, 324t

Tetanus-prone wounds, 26:323t

Tetanus toxoid, 26:323, 323t

Tetracaine (Amethocaine)

  • cream, 22:268t, 269
  • LET solution or gel, 22:268t, 269
  • TAC solution or gel, 22:267-269, 268t

Tetracycline

  • for CAP, 9:114t, 119, 10:140t
  • for chlamydia prophylaxis, 6:77t
  • digoxin interactions, 12:155

Thiazides, 12:155

Thiopental

  • cost of, 21:258t
  • for procedural sedation, 21:252

Thorazine. See Promethazine

Thrombocytopenia, heparin-induced, 15:183-184

Thromboembolism

  • burden of, 16:193-194, S02101:2-3
  • prevention of, 19:226
  • venous, 7:81-91, 14:163-171, 15:175-186
  • epidemiology of, 16:192-193
  • prophylaxis of, 16:191-200
  • risk factors for, 16:193, 193t

Thrombolytic therapy

  • agents for, 15:185, 185t
  • contraindications to, 15:185, 185t
  • indications for, 15:185, 185t
  • for VTE, 15:185

Thrombosis

  • calf vein, 15:186
  • cavernous sinus, 13:174-175
  • CLOT analysis, 16:199
  • deep venous (DVT)
  • diagnostic algorithm for, 14S
  • differential diagnosis of, 14:166t, 167
  • pre-test probability for, 14:167, 167t
  • prophylaxis of, S02101:1-7

Thumb fractures, 24:289t, 290

Thumb, gamekeeper’s, 24:292

Thyroid disease, Geriatric 2:1-2

Thyroid-stimulating hormone, Geriatric 2:1

Thyroid storm, Geriatric 2:7-8

  • diagnosis of, Geriatric 2:8
  • diagnostic criteria for, Geriatric 2:8t
  • laboratory diagnosis of, Geriatric 2:8-9
  • precipitants of, Geriatric 2:8t
  • treatment of, Geriatric 2:9-10, 9t

Thyrotoxicosis, 19:227, 228t

  • heart in, Geriatric 2:7
  • signs and symptoms of, Geriatric 2:6

Ticarcillin/clavulanate

  • for acute cholangitis, 17:208t
  • for CAP, 9:112t, 10:133, 137t
  • daily cost, 9:117t

Ticarcillin/tazobacatam, 9:112t, 10:137t

Tissue adhesives, 26:321

  • contraindications to, 26:320t
  • indications for, 26:319t
  • pearls and pitfalls with, 26:320t

Tissue plasminogen activator (tPA), 15:185, 185t

Tizanidine, 5:62

Tobramycin

  • for acute bacterial prostatitis, 3:35
  • ophthalmic ointment, 13:168t
  • ophthalmic solution, 13:168t

Tokyo, Japan, 2S:2-4

Tolmetin, 5:58

Topical anesthesia, 22:267-269, 268t

Topical antibiotics, 26:322

Tourniquet, penile, 3:33

Tramadol, 5:62

Transfusion triggers, Trauma 3:7

Tranylcypromine, 12:155

Trauma

  • in elderly, Trauma 3:9-10
  • eye injuries, 13:166-170
  • hand, 24:287-290
  • hand amputations, 24:296-297
  • initial management phase, Trauma 3:1-10
  • optic nerve, 13:170
  • in pediatric patients, Trauma 3:10
  • scrotal/testicular, 2:26

Trauma Bay, Trauma 3:2

Trauma resuscitation area, Trauma 3:2, 3f, 4f

Trauma resuscitation team, Trauma 3:3-4

Travel, 14:166

Trazadone, 12:155

Treatment regimens, 12:158

Triage after chemical exposures, 2S:2

Trichloroacetic acid (TCA), 6:77t

Trichomonas, 6:77t

Tricyclic antidepressants (TCAs)

  • drug interactions, 11:150
  • for pain management, 5:62-63

Trimethoprim/polymixin

  • ointment, 13:168t
  • solution, 13:168t

Trimethoprim/sulfamethoxazole (Bactrim)

  • for acute bacterial prostatitis, 3:35
  • for UTI, 1:10-11
  • warfarin interactions, 12:154, 155t

Trovafloxacin, 9:114t, 10:140t

Tunica vaginalis, 2:20-21, 21f

U

UFH. See Heparin, unfractionated

Ulcerative colitis, Geriatric 1:9

Ulcers

  • rectal, Geriatric 1:9
  • small intestinal, Geriatric 1:10

Ultrasound

  • Doppler, 2:22, 22f
  • venous, 14:168

Unconscious sedation, 21:248

Upper GI bleeding

  • acute, Geriatric 1:5f
  • sites of, Geriatric 1:8

Ureaplasma, 1:9

Urethral disorders, 3:35-37

Urethral forgeign bodies, 3:37

Urethral meatus, 6:74

Urethritis, 3:37

Urinary retention, in male patients, 3:35-36

Urinary tract infection, in women, 1:10-11

Urokinase, 15:185, 185t

Urologic emergencies, in male patients, 2:17-26, 3:29-38

Urologic examination, male, 2:18-19

Ursodiol, 17:209

Uterine fibroids, 1:13

Uveitis, 13:172

V

Vagina, 6:74

Vaginal vestibule, 6:73

Vaginosis, bacterial, 6:77t

Valacyclovir, 6:77t

Valproic acid, 5:63

Valsartan, 8:96t

Vancomycin, 9:112t, 114t, 10:136, 137t, 140t

Varicocele, acute, 2:25

Vascular anomalies

  • gastric, Geriatric 1:10
  • small bowel, Geriatric 1:10

Vasculitis, Geriatric 1:9-10

Vasodilators, 8:100, 100t, 102-105

Venography, 14:169-170

Valsartan, 8:96t

Vancomycin, 9:112t, 114t, 10:136, 137t, 140t

Varicocele, acute, 2:25

Vascular anomalies

  • gastric, Geriatric 1:10
  • small bowel, Geriatric 1:9-10

Vasculitis, Geriatric 1:9-10

Vasodilators, 8:100, 100t, 102-105

Venography, 14:169-170

Venous thromboembolism, 7:81-91, 14:163-171, 15:175-186. See also Deep venous thrombosis; Pulmonary embolism

  • anticoagulation therapy for, 15:181-183
  • assessment of, 14:167, 170-171
  • clinical evaluation of, 14:167-168
  • D-dimer test for, 14:170f, 171
  • diagnosis of, 14:167-168
  • invasive studies for, 14:169-170
  • pitfalls in, 14:171, 171t
  • systematic approach to, 14:170-171
  • tests for, 14:168-169
  • epidemiology of, 16:192-193
  • in medical patients, 14:165
  • patient risk stratification for, 16:194-195
  • pharmacologic strategies for, 16:192-193
  • prophylaxis of, 8:93-105, 16:194-195, S02101:7
  • enoxaparin vs. UFH, 16:199
  • exclusionary criteria for, 16:193, 196f
  • in hospitalized patients, 16:191-200, 193, 195f, 198f
  • LMHW strategies for, 16:199-200
  • nursing issues, 16:200
  • pathway for, 16:198f
  • pharmacoeconomic issues, 16:199
  • risk factors for, 14:165-167, 165t, 16:193, 193t
  • screening for, 16:192-193
  • thrombolytic therapy for, 15:185
  • travel and, 14:166
  • treatment of, 8:93-105, 15:178-179

Venous ultrasonography, 14:168

Ventilation, 22:266

Ventilation/perfusion (V/Q) scans, 14:168-169

Ventricular arrhythmias, 8:105

Ventricular rate control, 19:220, 222t

Verapamil

  • CCB interactions, 12:155
  • digoxin interactions, 12:155
  • for rate control in AF, 19:220, 222t
  • for SVT, 4:49, 4S

Versed. See Midazolam

Violence, intimate partner, 535Z:1-5

Visual acuity, 13:163-164

Visual loss

  • gradual, 13:175
  • sudden, 13:173-174

Vitreous hemorrhage, 13:173

Volar plate, 23:276, 277f, 24:290f

VX, 2S:3

W

Warfarin

  • for AF, 19:222, 226, 226t
  • drug interactions, 12:153-154, 155t
  • for DVT, 15:180-181
  • for VTE, 15:183

Wilson’s disease, 20:242

Wolff-Parkinson-White (WPW) syndrome, 4:46, 49-50, 19:226-227, 228t

Women, right lower quadrant abdominal pain in

  • algorithmic approach to, 1:1-13
  • differential diagnosis of, 1:2t, 3f, 4-13

Wound closure

  • methods of, 26:321-322
  • secondary or delayed primary, 26:319t
  • timing of, 26:320

Wound irrigation, 26:319-320

Wound management, 26:315-328

  • dressings, 26:322-323
  • evaluation, 26:316-317
  • post-repair care, 26:322-323
  • prophylactic antibiotics for, 26:323-324
  • tetanus prophylaxis, 26:324t

Wound preparation, 26:319

Wounds

  • animal bite, with increased risk for infection, 26:325t
  • combination, 26:316
  • crush, 26:316
  • epidemiology of, 26:315-316
  • puncture, 26:316
  • tetanus-prone, 26:323t
  •  
X

X-rays. See Radiography

Xylocaine. See Lidocaine

Z

Zebras, Geriatric 1:9-10

Zidovudine (AZT), 6:77t, 538Z:6t

Zipper injuries, 3:33


Financial Disclosure Statement

In order to reveal any potential bias in this publication, and in accordance with Accreditation Council for Continuing Medical Education guidelines, we present the following annual statement of disclosure of the editorial board members of Emergency Medicine Reports.

Paul S. Auerbach, MD; Brooks F. Bock, MD; Kenneth H. Butler, DO; Michael L. Coates, MD; Alasdair K.T. Conn, MD; David A. Kramer, MD; Larry B. Mellick, MD; Paul E. Pepe, MD; Robert Powers, MD; Barry H. Rumack, MD; David Sklar, MD; J. Stephan Stapczynski, MD; Steven M. Winograd, MD; and Allan B. Wolfson, MD, report no relationships with companies related to the field of study covered by this CME program.

Charles L. Emerman, MD
Consultant: Scios, Aventis
Speaker’s bureau: Scios, Pfizer, Roche, Aventis, and Sepracor.
Research: Scios, Aventis, Abbott

Kurt Kleinschmidt, MD
Speaker’s bureau: Aventis.

Charles V. Pollack Jr., MD
Consultant: Aventis, Schering-Plough, Milennium, Ischemia Technologies
Speaker’s bureau: Aventis, Shering-Plough, Milennium, BMS, Sanofi
Research: Aventis

David J. Robinson, MD
Consultant: Centocor
Speaker’s bureau: Centocor, Aventis

Steven G. Rothrock, MD
Stockholder: Gilead Sciences, Medtronic, Pfizer, Merck, Johnson/Johnson.

Sandra M. Schneider, MD
Stockholder: Roche

Corey M. Slovis, MD
Speaker’s bureau, consultant: Merck, Cor-Key, Genentech, and Wyeth-Ayerst.

David A. Talan, MD
Consultant: Bayer
Speaker’s bureau: Pfizer, Bayer, and Ortho-McNeil
Research: Bayer, OrthoMcNeil, Pfizer, Lilly, BMS, Astra-Zeneca
Research: Bristol-Myers, Bayer, and Eli Lilly.

Albert C. Weihl, MD
Consultant: Fugisawa Pharmaceuticals

Gideon Bosker, MD, editor-in-chief, is on the speaker’s bureau for Pfizer, Rhone-Poulenc Rorer, and Parke-Davis. Dr. Bosker also acknowledges that he receives royalties, commissions, and other compensation relating to the sale of textbooks, reprints of articles, and other written materials to the following pharmaceutical companies: Pfizer, Genentech, Aventis, Pharmacia, and Bayer.

William Brady, MD, Frederic H. Kauffman, MD, John A. Schriver, MD, Richard Saluzzo, MD, and Charles E. Stewart, MD, did not return disclosure forms.